Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.
The thrombin-catalysed conversion of plasma fibrinogen into fibrin and the development of an insoluble fibrin clot are the final steps of the coagulation cascade during haemostasis. A delicate balance between coagulation and fibrinolysis determines the stability of the fibrin clot. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) plays an important role in this process. TAFI is activated by thrombin and protects the fibrin clot against lysis. The role of TAFI in bleeding and thrombotic disorders is discussed as well as its novel emerging role in wound healing and inflammation.
Bouma
Bonno N
BN
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA. bouma@scripps.edu
Mosnier
Laurent O
LO
D001777:Blood Coagulation / Q000502:physiology*; D025901:Carboxypeptidase B2 / Q000502:physiology*; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans
D025901:Carboxypeptidase B2